Please login to the form below

Not currently logged in
Email:
Password:

Harren Jhoti and Will West join BIA board

UK biotech trade body welcomes CEOs of Astex Pharmaceuticals and CellCentric

The UK's BioIndustry Association (BIA) has appointed Harren Jhoti, CEO of Astex Pharmaceuticals, and Will West, CEO of CellCentric, to its board of directors.

They take over from Andrew Heath, managing director of Morvus, and Dominique Kleyn, CEO of London Genetics, who will stand down at the end of 2012.

The BIA, which represents the country's bioscience industry, also re-appointed Allan Marchington, partner at Apposite Capital, to the board.

All appointments will serve from January 1, 2013, for a term of two years.

Tim Edwards, BIA chairman, said: “As a result of these appointments, I believe our board continues to broaden its outlook and experience, and I look forward to working with them and the BIA team to ensure the UK remains a world-leading location for the life sciences.”

10th October 2012

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....